Plain-English translation of NCT07760480 on ClinicalTrials.gov ↗ · Source last updated ·
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether adding voclosporin to two standard lupus kidney medications—mycophenolate mofetil and —can reduce kidney inflammation more quickly than using the two standard medications alone. Researchers will compare how well the three-drug combination works versus the two-drug combination over 3 months, and will look at whether certain immune cell patterns can predict how well the treatment works long-term.
Lupus kidney disease is a serious complication that can damage your kidneys. Doctors want to know if this new addition to standard treatment can clear inflammation from the kidneys faster and more completely, which might improve outcomes and reduce the need for repeat kidney biopsies to check progress.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to receive either the three-medication treatment or the two-medication treatment. You'll have kidney biopsies before starting treatment and again after 3 months, and you'll provide blood and urine samples at multiple visits over up to 2 years to help researchers track how the medications are working. You'll also complete questionnaires about how you're feeling and attend regular clinic visits for monitoring.
AI-generated summary from trial data · Aug 12, 2026 · Not medical advice
Netherlands